Contact
searchSearch
HMP Global
Videos

Patel et al Video 5. We have exchanged for the ViperWire (CSI) and the Diamondback orbital atherectomy device (CSI) is used to prep the lesion.

11/13/2018

Video 5. We have exchanged for the ViperWire (CSI) and the Diamondback orbital atherectomy device (CSI) is used to prep the lesion. 

Read more at:

Guide Catheter Extension: Not Just for Complex Percutaneous Coronary Interventions

Nachiket J. Patel, MD, and Richard R. Heuser, MD, Phoenix Heart Center, Phoenix, Arizona


Subscriber

Cath Lab Digest Newsletter

Clinical & Industry News

ASC 6,000 milestone procedures
Arizona Centers
Arizona-Based Tri-City Cardiology's ASC Surpasses 6,000 Procedures, Marking a Major Milestone in Outpatient Cardiovascular Care
05/29/2026
"Delivering more than 6,000 procedures in an outpatient environment speaks to the strength of our team, the sophistication of our facility, and our commitment to cardiovascular treatment," said Bruce Stec, ASC administrator at Tri-City...
"Delivering more than 6,000 procedures in an outpatient environment speaks to the strength of our team, the sophistication of our facility, and our commitment to cardiovascular treatment," said Bruce Stec, ASC administrator at Tri-City...
"Delivering more than 6,000...
05/29/2026
Cath Lab Digest
Awards
ACC President Roxana Mehran, MD, FACC, Receives Andreas Grüntzig Ethica Award
05/28/2026
The award, named after Andreas Grüntzig, the pioneering German cardiologist who developed the first balloon angioplasty, is the highest honor presented by the Percutaneous Cardiovascular Registry (PCR).
The award, named after Andreas Grüntzig, the pioneering German cardiologist who developed the first balloon angioplasty, is the highest honor presented by the Percutaneous Cardiovascular Registry (PCR).
The award, named after Andreas...
05/28/2026
Cath Lab Digest
Cancer and Heart Disease
CARDIOCARE Project Celebrates Major Advances in Protecting Heart Health of Older Patients With Breast Cancer at Risk of Cardiotoxicity From Cancer Treatment
05/28/2026
Key takeaways: Project combines a wide range of data from more than 2,200 breast cancer patients to help the development of personalised AI-driven tools. Researchers have developed two dedicated applications to monitor both physical...
Key takeaways: Project combines a wide range of data from more than 2,200 breast cancer patients to help the development of personalised AI-driven tools. Researchers have developed two dedicated applications to monitor both physical...
Key takeaways: Project...
05/28/2026
Cath Lab Digest
Radiation Protection Systems
Cathpax Rolls Out New Radiation Protection System Nova-X® Across EMEA Following Very Promising Clinical Results
05/28/2026
Cathpax has signed several distribution contracts in different geographic regions and is supplying Nova-X® to various neurointerventional centers.
Cathpax has signed several distribution contracts in different geographic regions and is supplying Nova-X® to various neurointerventional centers.
Cathpax has signed several...
05/28/2026
Cath Lab Digest
CTO Viability
Rentrop Collateral Grade as an Angiographic Predictor of Myocardial Viability in Chronic Total Occlusion
05/28/2026
Your heart already has its own built-in bypass system that predicts whether the heart muscle is alive or dead, according to new research from the University of East Anglia and Norfolk and Norwich University Hospital. A new study reveals...
Your heart already has its own built-in bypass system that predicts whether the heart muscle is alive or dead, according to new research from the University of East Anglia and Norfolk and Norwich University Hospital. A new study reveals...
Your heart already has its own...
05/28/2026
Cath Lab Digest
Vertex Catheter (Jupiter Endovascular)
Pulmonary Embolism
Jupiter Endovascular Announces Positive Results From SPIRARE II Pivotal Trial at EuroPCR 2026
05/26/2026
The Vertex system leverages the company’s patented Transforming Fixation (TFX) platform technology in a novel catheter system designed to navigate flexibly through the right heart and then stabilize on-demand in the pulmonary arteries for...
The Vertex system leverages the company’s patented Transforming Fixation (TFX) platform technology in a novel catheter system designed to navigate flexibly through the right heart and then stabilize on-demand in the pulmonary arteries for...
The Vertex system leverages the...
05/26/2026
Cath Lab Digest
Uncontrolled Hypertension
AstraZeneca's Baxfendy Approved in U.S. as Aldosterone Synthase Inhibitor Treatment for Adults With Hypertension
05/26/2026
AstraZeneca’s Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood...
AstraZeneca’s Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood...
...
05/26/2026
Cath Lab Digest
Gene-Editing Approaches
Single Dose of Lilly's PCSK9 Base Editor, VERVE-102, Reduced PCSK9 by up to 88% and LDL-C by up to 62%, With Durable Effects Supporting Potential as One-Time Hypercholesterolemia Treatment
05/26/2026
Eli Lilly and Company announced positive Phase 1b Heart-2 study results for VERVE-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood low-density lipoprotein...
Eli Lilly and Company announced positive Phase 1b Heart-2 study results for VERVE-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood low-density lipoprotein...
Eli Lilly and Company announced...
05/26/2026
Cath Lab Digest
Inflammation
Cardiometabolic Clinical Data Support Potential of NodThera's Ruvonoflast to Treat Inflammation at the Source
05/26/2026
Boston, MA –  NodThera, a clinical-stage NLRP3 company developing a portfolio of potentially best-in-class brain-penetrant oral NLRP3 inhibitors to address inflammatory drivers of cardiometabolic and neurologic diseases, announced the...
Boston, MA –  NodThera, a clinical-stage NLRP3 company developing a portfolio of potentially best-in-class brain-penetrant oral NLRP3 inhibitors to address inflammatory drivers of cardiometabolic and neurologic diseases, announced the...
Boston, MA –  NodThera, a...
05/26/2026
Cath Lab Digest
Intravascular Lithotripsy
AVS, Now Part of Stryker, Enrolls First Patient in First-in-Human Coronary Intravascular Lithotripsy Study
05/21/2026
BOSTON--Amplitude Vascular Systems (AVS), a medical device company recently acquired by Stryker and focused on treating severely calcified arterial disease, announced the enrollment of the first patient in its first-in-human (FIH) study for...
BOSTON--Amplitude Vascular Systems (AVS), a medical device company recently acquired by Stryker and focused on treating severely calcified arterial disease, announced the enrollment of the first patient in its first-in-human (FIH) study for...
BOSTON--Amplitude Vascular...
05/21/2026
Cath Lab Digest

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use